TARS Overview

Tarsus Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics, starting with eye care. The Company’s lead product candidate, XDEMVY, is a lotilaner ophthalmic solution that targets and eradicates the root cause of Demodex blepharitis, Demodex mite infestation. The active pharmaceutical ingredient (API) of XDEMVY, lotilaner, paralyzes and eradicates mites and other parasites through the inhibition of parasite-specific gamma-aminobutyric acid-gated chloride channels. The Company is investigating the development of its product candidates to address targeted diseases with high unmet medical needs, which include TP-04, a novel ophthalmic gel formulation of lotilaner for the potential treatment of Ocular Rosacea, and TP-05, a novel investigational oral formulation of lotilaner, for potential Lyme disease prophylaxis and community malaria reduction.

Wall Street analysts forecast TARS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TARS is89.33 USD with a low forecast of 68.00 USD and a high forecast of 100.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Tarsus Pharmaceuticals Inc revenue for the last quarter amounts to 162.05M USD, increased 106.87

Tarsus Pharmaceuticals Inc. EPS for the last quarter amounts to -0.16 USD, decreased -75.00

Tarsus Pharmaceuticals Inc (TARS) has 370 emplpoyees as of May 14 2026.

Today TARS has the market capitalization of 2.78B USD.